Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Clinical Trials
Patient-Centered Clinical Pathways Should Incorporate the Patient’s Voice
Read More
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials
Read More
Delivering High-Value Personalized Interventions
Read More
Meeting Highlights
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Read More
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
Read More
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
Read More
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Read More
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
Read More
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
Read More
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
Read More
1
2
Page 1 of 2
Results 1 - 10 of 14